137 related articles for article (PubMed ID: 36815634)
1. Assessment of Structural Basis for Thiazolopyridine Derivatives as DNA Gyrase-B Inhibitors.
Zambre VP; Petkar NN; Dewoolkar VP; Bhadke SV; Sawant SD
Curr Drug Discov Technol; 2023; 20(4):e220223213933. PubMed ID: 36815634
[TBL] [Abstract][Full Text] [Related]
2. Thiazolopyridine ureas as novel antitubercular agents acting through inhibition of DNA Gyrase B.
Kale MG; Raichurkar A; P SH; Waterson D; McKinney D; Manjunatha MR; Kranthi U; Koushik K; Jena Lk; Shinde V; Rudrapatna S; Barde S; Humnabadkar V; Madhavapeddi P; Basavarajappa H; Ghosh A; Ramya VK; Guptha S; Sharma S; Vachaspati P; Kumar KN; Giridhar J; Reddy J; Panduga V; Ganguly S; Ahuja V; Gaonkar S; Kumar CN; Ogg D; Tucker JA; Boriack-Sjodin PA; de Sousa SM; Sambandamurthy VK; Ghorpade SR
J Med Chem; 2013 Nov; 56(21):8834-48. PubMed ID: 24088190
[TBL] [Abstract][Full Text] [Related]
3. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
Tomioka H
Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
[TBL] [Abstract][Full Text] [Related]
4. Design of novel quinoline-aminopiperidine derivatives as
Wang J; Zhao C; Tu J; Yang H; Zhang X; Lv W; Zhai H
J Biomol Struct Dyn; 2019 Jul; 37(11):2913-2925. PubMed ID: 30044186
[TBL] [Abstract][Full Text] [Related]
5. In silico study directed towards identification of the key structural features of GyrB inhibitors targeting MTB DNA gyrase: HQSAR, CoMSIA and molecular dynamics simulations.
Kamsri P; Punkvang A; Hannongbua S; Suttisintong K; Kittakoop P; Spencer J; Mulholland AJ; Pungpo P
SAR QSAR Environ Res; 2019 Nov; 30(11):775-800. PubMed ID: 31607177
[No Abstract] [Full Text] [Related]
6. Benzothiazinone-piperazine derivatives as efficient Mycobacterium tuberculosis DNA gyrase inhibitors.
Chandran M; Renuka J; Sridevi JP; Pedgaonkar GS; Asmitha V; Yogeeswari P; Sriram D
Int J Mycobacteriol; 2015 Jun; 4(2):104-15. PubMed ID: 26972878
[TBL] [Abstract][Full Text] [Related]
7. Docking and 3D QSAR Studies on Substituted Cyclobutylphenyl Quinoline Derivatives as Inhibitors of Bacterial DNA Gyrase.
Wani RR; Chaudhari HK
Curr Comput Aided Drug Des; 2018; 14(4):322-337. PubMed ID: 29766821
[TBL] [Abstract][Full Text] [Related]
8. Anti-tubercular Modelling via QSAR Approach, In Silico Design and Virtual Docking Screening of Designed Hypothetical Inhibitors Against DNA gyrase Protein.
Adeniji SE
Curr Comput Aided Drug Des; 2021; 17(6):739-758. PubMed ID: 32586260
[TBL] [Abstract][Full Text] [Related]
9. DNA topoisomerase I and DNA gyrase as targets for TB therapy.
Nagaraja V; Godbole AA; Henderson SR; Maxwell A
Drug Discov Today; 2017 Mar; 22(3):510-518. PubMed ID: 27856347
[TBL] [Abstract][Full Text] [Related]
10. Mycobacterium Tuberculosis (MTB) GyrB inhibitors: An attractive approach for developing novel drugs against TB.
Chaudhari K; Surana S; Jain P; Patel HM
Eur J Med Chem; 2016 Nov; 124():160-185. PubMed ID: 27569197
[TBL] [Abstract][Full Text] [Related]
11. Structure-based drug repurposing to inhibit the DNA gyrase of Mycobacterium tuberculosis.
Gl B; Rajput R; Gupta M; Dahiya P; Thakur JK; Bhatnagar R; Grover A
Biochem J; 2020 Nov; 477(21):4167-4190. PubMed ID: 33030198
[TBL] [Abstract][Full Text] [Related]
12. Mycobacterial DNA gyrB inhibitors: Ligand based pharmacophore modelling and in vitro enzyme inhibition studies.
Saxena S; Renuka J; Jeankumar VU; Yogeeswari P; Sriram D
Curr Top Med Chem; 2014; 14(17):1990-2005. PubMed ID: 25262795
[TBL] [Abstract][Full Text] [Related]
13. Spiropyrimidinetrione DNA Gyrase Inhibitors with Potent and Selective Antituberculosis Activity.
Govender P; Müller R; Singh K; Reddy V; Eyermann CJ; Fienberg S; Ghorpade SR; Koekemoer L; Myrick A; Schnappinger D; Engelhart C; Meshanni J; Byl JAW; Osheroff N; Singh V; Chibale K; Basarab GS
J Med Chem; 2022 May; 65(9):6903-6925. PubMed ID: 35500229
[TBL] [Abstract][Full Text] [Related]
14. In silico designing of domain B selective gyrase inhibitors for effective treatment of resistant tuberculosis.
Kashyap A; Singh PK; Silakari O
Tuberculosis (Edinb); 2018 Sep; 112():83-88. PubMed ID: 30205973
[TBL] [Abstract][Full Text] [Related]
15. Pharmacophore generation, atom-based 3D-QSAR and molecular dynamics simulation analyses of pyridine-3-carboxamide-6-yl-urea analogues as potential gyrase B inhibitors.
Azam MA; Thathan J
SAR QSAR Environ Res; 2017 Apr; 28(4):275-296. PubMed ID: 28399673
[TBL] [Abstract][Full Text] [Related]
16. Exploring the gyrase ATPase domain for tailoring newer anti-tubercular drugs: hit to lead optimization of a novel class of thiazole inhibitors.
Jeankumar VU; Kotagiri S; Janupally R; Suryadevara P; Sridevi JP; Medishetti R; Kulkarni P; Yogeeswari P; Sriram D
Bioorg Med Chem; 2015 Feb; 23(3):588-601. PubMed ID: 25541204
[TBL] [Abstract][Full Text] [Related]
17. Design of (quinolin-4-ylthio)carboxylic acids as new Escherichia coli DNA gyrase B inhibitors: machine learning studies, molecular docking, synthesis and biological testing.
Metelytsia L; Hodyna D; Dobrodub I; Semenyuta I; Zavhorodnii M; Blagodatny V; Kovalishyn V; Brazhko O
Comput Biol Chem; 2020 Apr; 85():107224. PubMed ID: 32018168
[TBL] [Abstract][Full Text] [Related]
18. Identification of Potent DNA Gyrase Inhibitors Active against
Pakamwong B; Thongdee P; Kamsri B; Phusi N; Kamsri P; Punkvang A; Ketrat S; Saparpakorn P; Hannongbua S; Ariyachaokun K; Suttisintong K; Sureram S; Kittakoop P; Hongmanee P; Santanirand P; Spencer J; Mulholland AJ; Pungpo P
J Chem Inf Model; 2022 Apr; 62(7):1680-1690. PubMed ID: 35347987
[No Abstract] [Full Text] [Related]
19. Identification of novel gyrase B inhibitors as potential anti-TB drugs: homology modelling, hybrid virtual screening and molecular dynamics simulations.
Maharaj Y; Soliman ME
Chem Biol Drug Des; 2013 Aug; 82(2):205-15. PubMed ID: 23614896
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and antitubercular activity of 4-alkoxy-triazoloquinolones able to inhibit the M. tuberculosis DNA gyrase.
Carta A; Bua A; Corona P; Piras S; Briguglio I; Molicotti P; Zanetti S; Laurini E; Aulic S; Fermeglia M; Pricl S
Eur J Med Chem; 2019 Jan; 161():399-415. PubMed ID: 30384044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
